Related Experiment Video

Updated: Oct 1, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.5K

Valproic Acid Inhibits Glioma and Its Mechanisms

Zhao-Yu Yang1, Xiao-Hong Wang2

  • 1Department of Neurosurgery, Dongying People's Hospital, Dongying 257091, Shandong, China.

Journal of Healthcare Engineering
|March 7, 2022
PubMed

Insights

Sodium valproate (VPA) inhibits glioma cell invasion and metastasis. This study reveals VPA alters Smad4 expression, a key factor in the epithelial-mesenchymal transition (EMT) process, offering a potential new target for glioma treatment.

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Glioma is a prevalent intracranial tumor globally.
  • Metastasis and chemoresistance pose significant challenges in glioma treatment.
  • Understanding the molecular mechanisms of glioma invasion is crucial for developing effective therapies.

Purpose of the Study:

  • To investigate the effect of sodium valproate (VPA) on glioma cell invasion and metastasis.
  • To elucidate the underlying molecular mechanisms, focusing on the epithelial-mesenchymal transition (EMT) pathway.
  • To evaluate VPA as a potential therapeutic agent targeting glioma progression.

Main Methods:

  • Glioma cell lines were treated with VPA at varying concentrations and durations.
  • Smad4 expression was manipulated using plasmid transfection and small interfering RNA (siRNA) in U87 cells.
  • Changes in EMT-related proteins were analyzed via Western blotting.
  • Immunohistochemistry was employed to assess Smad4, TIF1-γ, and TGF-β protein expression in clinical glioma specimens.

Main Results:

  • Sodium valproate (VPA) was found to inhibit the epithelial-mesenchymal transition (EMT) process in glioma cells.
  • VPA alters the expression level of Smad4, a critical component induced by TGF-β1.
  • The formation of a Smad3/4 complex, crucial for EMT, is affected by VPA, thereby inhibiting glioma cell invasion.

Conclusions:

  • Sodium valproate effectively inhibits glioma invasion and metastasis.
  • VPA exerts its antitumor effects by regulating Smad4 expression and consequently impacting the EMT pathway.
  • Targeting Smad4 through VPA presents a promising strategy for combating glioma progression.

More Related Videos

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

16.0K
Evaluating In Vitro DNA Damage Using Comet Assay10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

38.2K

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
750
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
489
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.8K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
557
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
560
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
673